Cargando…
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network
Castrate-resistant prostate cancer (CRPC) is poorly characterized and heterogeneous and while the androgen receptor (AR) is of singular importance, other factors such as c-Myc and the E2F family also play a role in later stage disease. HES6 is a transcription co-factor associated with stem cell char...
Autores principales: | Ramos-Montoya, Antonio, Lamb, Alastair D, Russell, Roslin, Carroll, Thomas, Jurmeister, Sarah, Galeano-Dalmau, Nuria, Massie, Charlie E, Boren, Joan, Bon, Helene, Theodorou, Vasiliki, Vias, Maria, Shaw, Greg L, Sharma, Naomi L, Ross-Adams, Helen, Scott, Helen E, Vowler, Sarah L, Howat, William J, Warren, Anne Y, Wooster, Richard F, Mills, Ian G, Neal, David E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023887/ https://www.ncbi.nlm.nih.gov/pubmed/24737870 http://dx.doi.org/10.1002/emmm.201303581 |
Ejemplares similares
-
HES5 silencing is an early and recurrent change in prostate tumourigenesis
por: Massie, Charles E, et al.
Publicado: (2015) -
Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013) -
Pro-neural transcription factors as cancer markers
por: Vias, Maria, et al.
Publicado: (2008) -
Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
por: Shah, Supriya, et al.
Publicado: (2016) -
He’s Come!!
por: Stewart, A. T.
Publicado: (1869)